NPM1 and acute myeloid leukemia: A related trial in adult patients with R/R NPM1-mutated or KTM2A-rearranged AML showed a 29% overall response rate and RNA-Seq analysis indicated downregulation of MEIS and HOXA9 genes and upregulation of differentiated antigens CD11b, CD14, and CD13 and actually has gone into phase 2 (NCT04065399).